Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;18(5):264-273.
doi: 10.1007/s11897-021-00526-x. Epub 2021 Sep 3.

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment

Affiliations
Review

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment

Alexandra Butters et al. Curr Heart Fail Rep. 2021 Oct.

Abstract

Purpose of review: We explore the sex-specific interaction of genetics and the environment on the clinical course and outcomes of hypertrophic cardiomyopathy (HCM).

Recent findings: Women account for approximately one-third of patients in specialist HCM centres and reported in observational studies. As a result, evidence informing clinical guideline recommendations is based predominantly on risk factors and outcomes seen in men. However, disease progression appears to be different between the sexes. Women present at a more advanced stage of disease, are older at diagnosis, have higher symptom burden, carry greater risk for heart failure and are at greater risk of mortality compared to men. Women are more likely to be gene-positive, while men are more likely to be gene-negative. The risk of sudden cardiac death and access to specialised care do not differ between the sexes. Reporting sex-disaggregated results is essential to identify the mechanisms leading to sex differences in HCM.

Keywords: Environment; Genetics; Hypertrophic cardiomyopathy; Sex.

PubMed Disclaimer

Conflict of interest statement

J. Ingles receives research grant support from MyoKardia Inc. N. Lakdawala has received modest consulting incomes from MyoKardia Inc., Bristol Myers Squibb, Pfizer Inc. and Tenaya.

Figures

Fig. 1
Fig. 1
Complex relationship of factors that determine the sex-related differences in hypertrophic cardiomyopathy
Fig. 2
Fig. 2
Sex differences in clinical profile, genotype and outcomes in hypertrophic cardiomyopathy
Fig. 3
Fig. 3
Sex distribution of original research studies used to inform clinical recommendations in the 2020 AHA 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy [2]

References

    1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254. doi: 10.1016/j.jacc.2015.01.019. - DOI - PubMed
    1. Ommen SR, Seema M, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation. 2020;142:e558–e631. - PubMed
    1. Ingles J, Goldstein J, Thaxton C, et al (2019) Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genom Precis Med 12:e002460 - PMC - PubMed
    1. Ingles J, Burns C, Bagnall RD, et al (2017) Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circulation: Cardiovascular Genetics 10:e001620 - PubMed
    1. Ho YC, Day MS, Ashley AE, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe) Circulation. 2018;138:1387–1398. doi: 10.1161/CIRCULATIONAHA.117.033200. - DOI - PMC - PubMed

Publication types